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SUMMARY
Osteoporosis is a common and debilitating condition
associated with signiﬁcant morbidity and mortality. The
efﬁcacy and safety of oral bisphosphonates for the treat-
ment of osteoporosis are well established. However,
patient adherence and persistence on treatment are sub-
optimal. This randomised open-label multi-centre study
of 6-months’ duration compared persistence on treatment
in postmenopausal women with osteoporosis receiving
either once-monthly ibandronate plus a patient support
programme (PSP), or once-weekly alendronate. To avoid
falsely elevated persistence rates often associated with
clinical trials, the study was designed to reﬂect everyday
clinical practice in the UK and follow-up visits were lim-
ited to be consistent with the primary care setting. Analy-
sis of the primary endpoint showed that persistence was
signiﬁcantly higher in the ibandronate/PSP group com-
pared with the alendronate group (p 0 0.0001). The
estimated proportion of patients persisting with treatment
at 6 months was 56.6% (306/541) and 38.6% (198/513)
in the ibandronate/PSP and alendronate groups, respec-
tively. Therefore, compared with alendronate, there was a
47% relative improvement in the proportion of patients
persisting with treatment in the ibandronate/PSP group.
Secondary endpoint measurements of adherence (e.g.
proportion of patients remaining on treatment at study
end; proportion of patients discontinuing from the study)
were also signiﬁcantly different in favour of ibandronate
plus patient support. In summary, the PERSIST study
demonstrated that persistence on treatment was increased
in patients receiving once-monthly ibandronate plus
patient support compared with once-weekly alendronate.
Increased persistence on bisphosphonate treatment is
expected to improve patient outcomes and decrease the
social and economic burden of osteoporosis.
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INTRODUCTION
‘The number one problem in treating illness today is the
failure of the patient to take prescription medications cor-
rectly’ (1). This statement from a recent American Heart
Association report clearly highlights the impact of poor treat-
ment adherence on patient health. The World Health
Organization (WHO) estimates that in developed countries,
just 50% of patients with chronic diseases adhere to their
recommended treatment regimens (2). Consequently, inter-
ventions to improve adherence may have a far greater impact
on patient health than advances in medical therapies (2).
Varying terminology is used to describe the extent to
which patients adhere to treatment (e.g. adherence, compli-
ance, persistence). Although the terms adherence and com-
pliance are often used interchangeably, adherence requires a
patient’s agreement to treatment recommendations and has
been deﬁned by the WHO as ‘the extent to which a per-
son’s behaviour – taking medication, following a diet, and/
or executing lifestyle changes, corresponds with agreed rec-
ommendations from a healthcare provider’ (2). The accu-
mulation of time from initiation to discontinuation of
treatment is referred to as ‘persistence’ (3).
Osteoporosis is a common, chronic – but frequently
asymptomatic – disease of the skeleton associated with low
rates of treatment adherence and persistence (4,5). Despite
its sometime ‘silent’ nature, osteoporosis is a debilitating
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fragility fractures and associated morbidity and mortality
(6). Poor persistence with osteoporosis medications increases
fracture risk, impairs patients’ quality of life and raises both
direct and indirect healthcare costs (5).
Oral bisphosphonates are usually the ﬁrst-line treatment
option for postmenopausal osteoporosis, and their effective-
ness in increasing bone mineral density (BMD), normalising
bone turnover and reducing the risk of fracture is well
established (6). However, the usefulness of bisphosphonates
in clinical practice is often compromised by poor adherence
and persistence on treatment (5). In the UK, the National
Institute of Clinical Excellence (NICE) acknowledges the
importance of adherence, and states that an ‘unsatisfactory
response to bisphosphonate treatment’ involves the occur-
rence of another fragility fracture despite full adherence with
treatment (7).
Complex dosing instructions are necessary to maximise
the bioavailability of bisphosphonates and reduce the risk of
adverse events, and there is a growing body of evidence sug-
gesting that reduced adherence to these agents is associated
with increased dosing complexity (4,5,8,9). Interestingly,
studies in other disease states have shown that reducing the
complexity and frequency of dosing regimens improves
adherence and persistence (10,11).
Attempts to improve adherence in patients with osteopor-
osis include the development of weekly and monthly oral
bisphosphonates that require less frequent dosing than stand-
ard once-daily formulations. Indeed, the once-weekly formu-
lation of alendronate is associated with improved adherence
compared with daily alendronate (12). However, adherence
to weekly bisphosphonates remains suboptimal, with studies
reporting one-year adherence and persistence rates of 050%
(12,13). In a longitudinal cohort study of over 200,000
women, only 25% of patients who were new to bisphospho-
nate treatment and received prescriptions for weekly alendro-
nate or risedronate, achieved levels of adherence adequate to
ensure anti-fracture efﬁcacy (13). The DIN-LINK general
practice database (CompuFile Ltd, Woking, UK) compiles
data from longitudinal patient records across the UK, and
reports ‘real-life’ persistence rates of 50–55% 6 months after
the initiation of treatment with weekly alendronate (14).
The once-monthly oral formulation of the bisphosphonate
ibandronate (also known as ibandronic acid) has been shown
to be as effective and well-tolerated as once daily ibandronate
(15). In a recent randomised cross-over study, 66% of
patients preferred the once-monthly dosing regimen of
ibandronate to the once-weekly dosing regimen of alendro-
nate (16). Although it is possible that once-monthly treat-
ment regimens may lead to improved persistence, this has
not yet been investigated in randomised controlled studies.
To improve the effectiveness of bisphosphonate treat-
ment, a patient support programme for once-monthly
ibandronate has been developed. This programme is cur-
rently available, free-of-charge, to all patients prescribed
ibandronate in the UK. The PERSIST study (PERsistence
Study of Ibandronate verSus alendronaTe) was a random-
ised, open-label multi-centre study of 6 months’ duration
designed to assess persistence on treatment within a ‘real-
life’ primary care setting in the UK. The objective of PER-
SIST was to determine whether once-monthly dosing with
ibandronate, coupled with the ibandronate patient support
programme, would improve persistence on treatment com-
pared with once-weekly alendronate.
METHODS
Patients
Postmenopausal women with osteoporosis were eligible for
inclusion in the study. Diagnoses of osteoporosis were based
upon the clinical judgement of each patient’s primary care
General Practitioner (GP). Assessment of BMD by densi-
tometry was not compulsory. Eligible patients were required
to be independent and self-caring, and able to comply with
bisphosphonate dosing requirements. In particular, patients
had to be able to observe a pre- and post-dose fasting inter-
val and maintain an upright posture for 1 h following bis-
phosphonate dosing. The main exclusion criteria were:
previous or current treatment with a bisphosphonate; hyper-
sensitivity to bisphosphonates; and abnormalities of the
oesophagus causing delayed oesophageal emptying.
The study protocol and any written information to be
provided to patients were submitted to an Independent Eth-
ics Committee (IEC) complying with local regulatory
requirements. Written approval for the study was obtained
from the Medicines and Healthcare products Regulatory
Agency (MHRA), the South-East Multicentre Research
Ethics Committee (MREC), and Local Research Ethics
Committees (LRECs) and Primary Care Trusts (PCTs) for
each study centre. The study was conducted in accordance
with the Good Clinical Practice guidelines of the Interna-
tional Conference on Harmonisation of Technical Require-
ments for Registration of Pharmaceuticals for Human Use
(ICH), and the principles of the Declaration of Helsinki.
All patients provided written informed consent.
Study Design and Treatment
Design
This open-label study was conducted in 103 primary care
centres in the UK between 21 January 2005 and 18 January
2006. After a screening period of up to 30 days, eligible
patients were randomised in a 1:1 ratio to receive either oral
ibandronate (150 mg single tablet, once monthly) or oral
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6 months. Patients assigned to receive ibandronate were also
enrolled into the patient support programme, and constitu-
ted the ‘ibandronate/PSP group’. Randomisation was strati-
ﬁed according to age (070 years of age and  70 years of
age) and was achieved using a randomised allocation sche-
dule (based on block randomisation within age strata), with
details provided to investigators in envelopes.
The study protocol allowed randomisation to be per-
formed on the same day as the initial screening visit, provi-
ding the patient had sufﬁcient time to consider participating
in the study. In addition to the screening and randomisa-
tion visits, only one further visit was planned; this was a
ﬁnal visit at the end of the study at 6 months. In keeping
with everyday clinical practice, GPs and/or patients could
plan intermediate visits according to personal needs and
practice policies.
Treatment
To reﬂect a ‘real-life’ setting, study medication was obtained
through dispensing pharmacists. A GP at each study centre
was linked to a nominated pharmacist. For each patient, the
GP completed, and retained on ﬁle, a proforma indicating
treatment assignment (ibandronate/PSP or alendronate).
Patients subsequently presented identical copies of the pro-
forma to the nominated pharmacists who then dispensed
1-month’s study medication. Every month, up to the end of
the study at six months, patients could obtain proformas
using the normal repeat prescribing process employed by
each GP’s practice (e.g. telephoning the practice reception
or a practice nurse). Patients then ‘ﬁlled the prescription’ by
providing the proforma to their dispensing pharmacist and
obtaining that month’s medication. Patients were free to
withdraw from the study at any time.
Patients were instructed to take ibandronate or alendro-
nate in the morning, after an overnight fast, in an upright
position and with a full glass of plain water. Patients were
to remain fasting and in an upright position for at least 30
or 60 min after dosing with alendronate and ibandronate
respectively. Concomitant treatment with hormone replace-
ment therapy and/or calcium and Vitamin D was permit-
ted; details of all concomitant medications were recorded.
Patient support programme
The dispensing pharmacists were responsible for faxing
patients’ contact details to the providers of the ibandronate
patient support programme (International SOS Assistance
(UK) Ltd, London, UK). This programme is available to all
patients prescribed once-monthly ibandronate in the UK;
there is no equivalent support programme available to
patients prescribed once-weekly alendronate. Therefore, to
reﬂect current UK practice, only patients randomised to
receive ibandronate were enrolled into the programme.
Following an initial telephone call, patients enrolled into
the patient support programme received a welcome-pack
providing basic information about osteoporosis. Between 1
and 3 days prior to each scheduled monthly dose, patients
received a telephone call to remind them to take their medi-
cation. During each call, patients were provided with rele-
vant dosing instructions, and information about
osteoporosis and the importance of long-term adherence to
treatment. All telephone contact with patients was carried
out by trained nurses. A newsletter was also sent to patients
3 months after enrolment into the programme. Patients
were free to withdraw from the patient support programme
after 3 months of treatment.
Study Endpoints
Primary endpoint
The primary endpoint of the study was persistence on treat-
ment of patients receiving once-monthly ibandronate with
the patient support programme vs. that of patients receiving
once-weekly alendronate. The measurement of persistence
employed during the study was based on the number of
consecutive months of study medication dispensed to the
patient by the nominated pharmacists (i.e. the number of
‘prescription reﬁlls’). Speciﬁcally, persistence was deﬁned as
the number of days from the date of randomisation to the
date of the ﬁrst failure to persist (i.e. the time-to-failure-to-
persist). A patient was classiﬁed as failing to persist if she
withdrew from the study or missed one prescription cycle.
Therefore, a patient who failed to ﬁll 1 month’s prescrip-
tion was considered non-persistent for the remainder of the
study, regardless of whether she collected medication for
one or more subsequent months.
Patients were allowed a window of  14 days to ﬁll each
month’s prescription. The date of failure was deﬁned as the
date of the last ﬁlled prescription prior to failure plus
30 days, or the date of withdrawal, whichever occurred ﬁrst.
Secondary endpoints
Secondary endpoints were (i) the number of patients who
discontinued treatment; (ii) the number of patients who had
at least ﬁve of the six prescriptions ﬁlled; and (iii) the num-
ber of patients remaining on treatment at the end of the
study (i.e. patients who had their sixth prescription ﬁlled).
Safety Analyses
Investigators were asked to record any adverse event experi-
enced by patients, irrespective of the suspected relationship
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graded according to severity (mild, moderate or severe). The
safety population included all randomised patients who pro-
vided safety data while receiving study medication.
Adverse event proﬁles presented are for treatment-emer-
gent adverse events (i.e. adverse events with a recorded start
date beyond or equal to the date of randomisation). If the
start date of a reported adverse event was missing, this was
considered a treatment-emergent adverse event.
Statistical Analyses
Sample size calculation
The sample size calculation was based on the primary end-
point (persistence on treatment). Assumptions for the per-
sistence rate on alendronate were based on data from the
DIN-LINK general practice database showing persistence
rates of 50–55% at 6 months for patients in a ‘real-life’ pri-
mary care setting during the years 2002 and 2003 (14). It
was assumed that, despite the naturalistic design of the
study, persistence in the alendronate group would be artiﬁ-
cially increased to 60% at 6 months.
Using a log-rank test at a two-sided 5% level of signiﬁ-
cance, 476 patients per treatment group would be sufﬁcient
to detect, with 90% power, a difference between a propor-
tion of persisting patients of 60% in the alendronate group
and 70% in the ibandronate/PSP group. This assumed a
constant hazard ratio of 1.43 (i.e. patients in the alendronate
group were 1.43 times more likely to fail to persist than
patients in the ibandronate/PSP group). The planned total
number of patients to be recruited for the study was 1000.
Futility analysis
To permit valid interpretation of the persistence data, it was
ﬁrst necessary to determine whether the study accurately
reﬂected routine clinical practice in the UK. A preplanned
futility analysis was therefore performed, which sought to
compare persistence rates observed at 4 months in the
alendronate group with those reported in UK general prac-
tice records (DIN-LINK database).
The futility analysis was performed once the 280th
alendronate patient had either completed 4 months of treat-
ment or was withdrawn from the study. With a sample size
of 280 in the alendronate group, a one-group v
2-test with a
2.5% one-sided signiﬁcance level would have 80% power to
detect the difference between the clinical practice persistence
rate (62%) calculated from the record database, and a hypo-
thetically elevated persistence rate of 70% in the alendronate
group. The null hypotheses – that the proportion of
patients in the alendronate group persisting with treatment
was equal to 62% – was rejected if the p-value from a one-
sided, one-group proportion test (with a continuity correc-
tion) was 00.05. Deviation from persistence rates available
from GP record databases would have implied that study
participation inﬂuenced patient behaviour, and thus ren-
dered the study ﬁndings invalid.
Analyses of study endpoints.
Study endpoint analyses were performed for the intent-to-
treat (ITT) population, which included all patients in the
safety population who provided at least one primary end-
point measurement (i.e. had ﬁlled at least one prescription).
For the primary endpoint, time-to-failure-to-persist data
were used to construct Kaplan–Meier curves for the two
treatment groups. The statistical signiﬁcance of the differ-
ence between the distributions of the curves was tested using
log-rank and Wilcoxon–Gehan tests. These analyses were
performed using SAS
  LIFETEST (SAS Institute, Cary,
NC, USA). In a second analysis, a Cox’s proportional haz-
ards model was ﬁtted to the time-to-failure-to-persist data
with adjustments for the stratiﬁcation variable (patient age).
This model was used to compare the likelihood of failure in
the two treatment groups.
RESULTS
Patient Disposition and Baseline Characteristics
A total of 1103 patients consented to participate in the
study, with 561 and 542 patients randomised to the ibandr-
onate/PSP and alendronate groups respectively. The safety
population included 1077 patients (ibandronate/PSP group,
n ¼ 548; alendronate group, n ¼ 529). Persistence data for
one patient in the ibandronate/PSP group were unavailable
for analysis and this patient was excluded from the ITT
population (N ¼ 1076).
Baseline demographics and characteristics were similar
between treatment groups (Table 1). Patients were postmen-
opausal women with a mean age of 67.8 years. T-scores
from previous BMD assessments were known for 130% of
patients.
Futility Analysis
The rate of persistence in the alendronate group at four
months (145/278, 52.2%) was not elevated in comparison
with rates of persistence to alendronate treatment in routine
clinical practice calculated from the DIN-LINK general
practice database (62%). The futility analysis conﬁrmed that
alendronate persistence rates in the study were statistically
different, and slightly lower, than those in clinical practice
(z ¼ )3.319; one-sided p ¼ 0.0005). It was therefore con-
sidered appropriate to continue with the study.
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Primary endpoint
Analysis of the primary endpoint showed that persistence on
treatment was signiﬁcantly higher in the ibandronate/PSP
group compared with the alendronate group. The estimated
proportion of patients persisting with treatment at six
months was 56.6% (306/541; 95% CI: 52.3%, 60.6%) and
38.6% (198/513; 95% CI: 34.4%, 42.8%) in the ibandro-
nate/PSP and alendronate groups respectively. Therefore,
compared with the alendronate group, there was a 47% rel-
ative improvement in the proportion of patients persisting
with treatment in the ibandronate/PSP group. Kaplan–
Meier curves for the two treatment groups were constructed
with the time-to-failure-to-persist data and represent the
probability of an individual patient persisting with treat-
ment over time (Figure 1). The distributions of the
Kaplan–Meier curves for the two treatment groups were
signiﬁcantly different, with the probability of persistence
signiﬁcantly higher in the ibandronate/PSP group
(p 0 0.0001, log-rank and Wilcoxon–Gehan tests).
The median time-to-failure-to-persist in the alendronate
group was 136 days (95% CI: 111, 142). It was not
possible to calculate the median time-to-failure-to-persist for
the ibandronate/PSP group because 150% of patients in
this group were persistent at the end of the study. The
mean ( SEM) time-to-failure-to-persist was 122 ( 2.5)
and 109 ( 2.5) days in the ibandronate/PSP and alendro-
nate groups respectively.
As indicated in Figure 1, a slightly higher proportion of
patients in the alendronate group persisted with treatment
during the ﬁrst month. This initial trend was not statisti-
cally signiﬁcant (p ¼ 0.212), and reversed after 30 days.
The probability of persistence was higher in the ibandro-
nate/PSP group for the remainder of the study. For patients
who persisted with treatment beyond day 30, the estimated
hazard ratio for patients in the ibandronate/PSP group vs.
patients in the alendronate group was 0.538 (95% CI:
0.44, 0.66; p 0 0.0001). Therefore, beyond day 30,
patients in the ibandronate/PSP group were approximately
half as likely to fail to persist as patients treated with
alendronate.
Secondary endpoints
A total of 241 patients discontinued from the study
(Table 2). Signiﬁcantly more patients discontinued from the
Table 1 Baseline patient demographics and characteristics for the intent-to-treat (ITT) population
Ibandronate/PSP (n ¼ 547) Alendronate (n ¼ 529)
Age [mean (SEM) years] 67.8 (0.4), n ¼ 541 67.8 (0.4), n ¼ 513
Ethnic group, n (%)*
Caucasian 533 (98.5) 507 (98.8)
Black 1 (0.2) 4 (0.8)
Oriental 3 (0.6) 2 (0.4)
Other 4 (0.7) 0 (0)
BMD, n (%)*
Known 171 (31.9) 168 (33.1)
Not known 365 (68.1) 340 (66.9)
T-score in patients with known BMD assessment, mean (SEM) )2.42 (0.07), n ¼ 171 )2.45 (0.07), n ¼ 168
Clinically signiﬁcant ﬁndings on physical examination, n (%)*
Yes 75 (14.1) 67 (13.3)
No 457 (85.9) 436 (86.7)
Time since onset of menopause, mean (SEM) years 21.7 (0.5), n ¼ 382 21.8 (0.5), n ¼ 372
Family history of osteoporosis, n (%)*
Yes 186 (34.5) 188 (36.8)
No 353 (65.5) 323 (63.2)
Subjects reporting medical history, n (%)* 520 (96.3) 496 (96.7)
For patients with medical history, n (%)
No previous fractures 288 (55.4) 275 (55.4)
1 previous fracture 165 (31.7) 151 (30.4)
2 previous fractures 47 (9.0) 49 (9.9)
3–5 previous fractures 20 (3.8) 21 (4.2)
For patients with previous fracture(s)
Time since last fracture, mean (SEM) years 7.0 (0.6), n ¼ 230 7.6 (0.7), n ¼ 220
PSP, patient support programme. *Percentages are based on the number of ITT patients for whom relevant data were available. The site of bone mineral
density (BMD) assessment varied and included the spine, hip and forearm.
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with the ibandronate/PSP group (107/547, 19.6%; p ¼
0.023). The most common reasons for discontinuation were
adverse events (n ¼ 127) and patient withdrawal from the
study (n ¼ 40).
The proportion of patients who had at least ﬁve of the
six prescriptions ﬁlled was signiﬁcantly higher in the ibandr-
onate/PSP group compared with the alendronate group
(p ¼ 0.008; Table 3). Similarly, the proportion of patients
who remained on treatment at the end of the study and
had their sixth prescription ﬁlled was signiﬁcantly higher in
the ibandronate/PSP group (p ¼ 0.014; Table 3).
Persistence stratiﬁed by age
Results for the two age strata (070 years and  70 years of
age) were similar to those for the whole study cohort.
Within both age strata, Kaplan–Meier analyses showed sig-
niﬁcant differences in the primary endpoint of persistence
on treatment in favour of the ibandronate/PSP group
(070 years, p 0 0.0006;  70 years, p ¼ 0.002; Wil-
coxon–Gehan tests). There was no signiﬁcant difference in
the primary endpoint between the two age strata, either
before or after day 30 of the study ( 30 days, p ¼ 0.797;
130 days, p ¼ 0.431; Wald test).
Safety
A similar proportion of patients in the ibandronate/PSP
group [371/542 (68.5%)] and alendronate group [381/513
(74.3%)] experienced at least one adverse event. The major-
ity of adverse events were mild or moderate in severity. A
higher proportion of adverse events were considered possibly
related to study treatment in the ibandronate/PSP group
[155/904 (17.1%)] compared with the alendronate group
[104/892 (11.7%)]. However, similar proportions of adverse
events were considered probably related to study treatment
[63/904 (7.0%) and 58/892 (6.5%) in the ibandronate/PSP
and alendronate groups respectively]. There was no signiﬁ-
cant difference between treatment groups in the proportion
of patients discontinuing the study because of adverse events
(p ¼ 0.934; Table 2).
Treatment-emergent adverse event proﬁles were compar-
able between treatment groups (Table 4). Gastrointestinal
disorders and musculoskeletal/connective tissue disorders
were the most commonly reported adverse events. Overall,
Table 2 Patient discontinuations for the
intent-to-treat (ITT) population Ibandronate/PSP
(n ¼ 547)
Alendronate
(n ¼ 529)
p-value
(v
2 test)
No. (%) patients discontinued from the study 107 (19.6) 134 (25.3) 0.023
Primary reason for discontinuation, n (%)
Adverse event 65 (11.9) 62 (11.7) 0.934
Withdrew from study 19 (3.5) 21 (4.0) –
Administrative reason 0 (0) 4 (0.8) –
Protocol violation 4 (0.7) 5 (0.9) –
Lost to follow-up 8 (1.5) 14 (2.6) –
Withdrew consent 6 (1.1) 16 (3.0) –
Other 5 (0.9) 12 (2.3) –
PSP, patient support programme.
Figure 1 Kaplan-Meier curves for
patients in the ibandronate/patient support
programme (PSP) and alendronate groups.
Time-to-failure-to-persist data for the
intent-to-treat (ITT) population were used
to estimate the probability of persistence at
each time-point. Data for patients
persisting with treatment at the end of the
study were censored, to indicate that the
period of observation was cut off before
the event of interest (e.g. failing to persist
with treatment) occurred. The censoring
time was deﬁned as the last prescription
ﬁlled/dispensed plus 30 days
RESULTS OF THE PERSIST STUDY 901
ª 2006 The Authors
Journal compilation ª 2006 Blackwell Publishing Ltd Int J Clin Pract, August 2006, 60, 8, 896–905similar results were reported in the two age strata (070
and  70 years of age). However, gastrointestinal disorders
were reported in a higher proportion of patients aged
070 years compared with patients aged  70 years [140/
609 (23.0%) and 91/468 (19.4%) respectively].
In patients aged 070 years, musculoskeletal and connec-
tive tissue disorders were more common in the alendronate
group [occurring in 74 of a total of 214 patients experien-
cing treatment-emergent adverse events (34.6%)] compared
with the ibandronate/PSP group [63/214 (29.4%)]. How-
ever, this trend was reversed in patients aged  70 years,
with musculoskeletal and connective tissue disorders more
common in the ibandronate/PSP group compared with the
alendronate group [60/157 (38.2%) and 57/166 (34.3%),
respectively].
CONCLUSIONS
This randomised, controlled study compared persistence on
treatment in postmenopausal women receiving monthly
ibandronate (150 mg) plus patient support, or weekly
alendronate (70 mg). The study was designed to reﬂect
everyday clinical practice and to avoid falsely elevated per-
sistence rates often reported in the clinical trial setting.
The primary endpoint of the study – persistence on treat-
ment – was signiﬁcantly greater in patients receiving ibandr-
onate plus patient support compared with patients receiving
alendronate. By the end of the study at 6 months, there was
an 18% absolute difference between the ibandronate/PSP
and alendronate groups in the proportion of patients per-
sisting with treatment. With 39% of patients persisting on
treatment in the alendronate group at 6 months, this abso-
lute difference represents an approximately 47% improve-
ment in persistence for patients receiving once-monthly
ibandronate plus patient support. Indeed, hazard ratio ana-
lyses revealed that, from day 30 until the end of the study
at 6 months, patients in the ibandronate/PSP group were
approximately half as likely to cease treatment compared
with patients receiving alendronate. Results were consistent
across all age strata.
The deﬁnition of persistence employed in the study was
stringent but consistent with other similar studies and the
DIN-LINK UK general practice database (12,14,17). In
PERSIST, patients failing to ﬁll their monthly prescription
within 14 days of the expected date were considered non-
persistent. A patient who, for example, failed to persist at
month 2 but subsequently collected medication as expected
during months 3–6, would have been classiﬁed as a non-
persisting patient from month 2 onwards. Secondary end-
points measuring patient adherence were also employed
during this study. The proportion of patients remaining on
treatment at the end of the study, estimated from the num-
ber of patients reﬁlling a prescription at 6 months, was sig-
niﬁcantly higher in the ibandronate/PSP group compared
with the alendronate group (75% vs. 68%). Similarly, the
number of discontinuations (20% vs. 25%) and the number
Table 4 Adverse events in the safety
population. Treatment-emergent adverse
events (TEAEs) were deﬁned as adverse
events with a recorded start date beyond
or equal to the date of randomisation
Ibandronate/PSP
(n ¼ 548)
Alendronate
(n ¼ 529)
No. patients with at least 1 TEAE 371 380
TEAEs, n (%)* patients
Gastrointestinal disorders 122 (32.9) 109 (28.7)
General disorders and administration site conditions 44 (11.9) 42 (11.1)
Infections and infestations 103 (27.8) 111 (29.2)
Musculoskeletal and connective tissue disorders 123 (33.2) 131 (34.5)
Nervous system disorders 54 (14.6) 39 (10.3)
Respiratory, thoracic and mediastinal disorders 37 (10.0) 49 (12.9)
Skin and subcutaneous tissue disorders 35 (9.4) 42 (11.1)
PSP, patient support programme. *Percentages are based on the number of patients in the safety popu-
lation with at least one treatment-emergent adverse event. Data are presented for TEAEs occurring in
 10% of patients who experienced at least one TEAE in either treatment group.
Table 3 Secondary endpoints for the
intent-to-treat (ITT) population Ibandronate/PSP
(n ¼ 547)
Alendronate
(n ¼ 529)
p-value
(v
2 test)
No. (%)* patients with at least
ﬁve prescriptions ﬁlled
434 (80.2) 376 (73.3) 0.008
No. (%)* patients with sixth
prescription ﬁlled
405 (74.9) 349 (68.0) 0.014
PSP, patient support programme. *Percentages are based on the number of ITT patients for whom
relevant data were available.
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(80% vs. 73%), were also statistically different in favour of
patients receiving ibandronate plus patient support.
Cross-study comparisons of persistence rates are invalid
unless the deﬁnitions of persistence employed are similar.
Boccuzzi et al. (17) used a similar deﬁnition to that employed
in the PERSIST study, and reported persistence rates over
12 months for daily and weekly alendronate of 19% and
22% respectively. Persistence rates at 12 months of 32% and
44% for daily and weekly alendronate were reported by
Cramer et al. (12) in another study that employed a similar
deﬁnition of persistence. Higher rates of persistence at
12 months (67–84%) were reported in a UK study of daily
raloxifene treatment; however, persistence was deﬁned less
stringently as ‘continuing to take tablets for more than seven
of any 14 days immediately before the 1-year visit’ (18).
Tolerability issues, in particularly gastrointestinal adverse
events, are a signiﬁcant cause of early discontinuation from
bisphosphonate treatment (5). Both ibandronate and alendr-
onate were well tolerated during the PERSIST study. Unsur-
prisingly, given the patient population and study medication,
gastrointestinal and musculoskeletal/connective tissue disor-
ders were the most commonly reported adverse events.
One potential limitation of PERSIST was the 6-month
duration of the study. However, data from a GP record
database in the UK indicate that rates of persistence on
weekly alendronate begin to stabilise approximately
3 months after the start of treatment (14). Indeed, persist-
ence rates in the PERSIST study declined at a slower rate
after the third month of treatment. It is not unreasonable to
suggest that most of the patients who were persistent with
treatment at 6 months were likely to continue with treat-
ment beyond this point.
The efﬁcacy of bisphosphonate treatment was not meas-
ured during the PERSIST study. The safety and efﬁcacy of
the bisphosphonates are well established (6), and the objec-
tive of PERSIST was to measure and compare persistence
on treatment of patients receiving two commonly prescribed
bisphosphonate preparations. Although persistence rates
obtained from prescription data do not equate exactly to
rates of patient adherence to medication, the measurement
of prescription reﬁlls is a well-established method of indi-
rectly monitoring adherence and persistence on treatment.
There is no standard method of measuring adherence, and
other methods such as the biochemical analysis of drug con-
centrations in the blood or urine are costly and inconveni-
ent for patients (19).
Compared with clinical practice, adherence to treatment
in a clinical trial setting may be enhanced and result in fal-
sely elevated persistence treatment rates. Trial selection cri-
teria may be biased towards patients more likely to adhere
to treatment and, once selected, trial patients may be affor-
ded longer consultation times and provided with more
information about their medication than patients in clinical
practice. The PERSIST study was designed to reﬂect every-
day clinical practice and to minimise the impact of trial par-
ticipation on persistence rates. Patients requested and
obtained each month’s medication via a method very similar
to that employed in most primary care centres in the UK.
The futility analysis showed that, 4 months into the study,
persistence in the alendronate group was not elevated com-
pared with ‘real-life’ persistence data from a computerised
GP record database.
In keeping with the naturalistic design of the study,
patients randomised to receive ibandronate were also
enrolled into a patient support programme. This pro-
gramme is available to all patients in the UK who are
prescribed once-monthly ibandronate. Patients enrolling in
the programme are provided with monthly reminder tele-
phone calls and are able to obtain advice on osteoporosis
and their medication. Patient support programmes are
increasingly used to improve adherence and persistence in
chronic conditions such as obesity (20), and are consistent
with calls to involve patients in any initiative designed to
improve treatment adherence (19). In a recent UK study,
patient support – in the form of treatment monitoring by
nurses – improved adherence by 57% and increased the
average length of time patients persisted with treatment by
25% (18). In the same study, monitoring by nurses had a
greater impact on adherence and persistence than the provi-
sion of bone marker results to patients. To date, there is no
patient support programme in the UK for patients pre-
scribed weekly alendronate. In the PERSIST study, enrol-
ment of patients randomised to receive alendronate into
a patient support programme would therefore not have
reﬂected UK clinical practice.
Although calculating the effect of increased persistence on
fracture risk and other measures of bisphosphonate efﬁcacy
was beyond the scope of this 6-month study, the available
evidence suggests that adherence to treatment is associated
with improved patient outcomes. Various studies have
shown that increases in BMD are greater in patients who
strictly adhere to oral bisphosphonate regimens (21–23). In
a UK-based randomised controlled study, Clowes et al. (18)
demonstrated an association between adherence to osteo-
porosis treatment and positive changes in hip BMD and
bone-marker resorption (18). Fracture rates are also lower
in patients with osteoporosis who adhere to treatment.
Studies in clinical practice showed that patients who
adhered to various osteoporosis medications experienced a
16% lower fracture rate and a 24% reduction in fracture
risk compared with non-adherent patients (24,25). In
another study, adherence to bisphosphonate treatment was
associated with a 36% reduction in the relative risk of hip
fracture over 2 years (26). As well as improving patient
outcomes, increased adherence and persistence is likely to
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porosis treatment.
In summary, the PERSIST study demonstrated that per-
sistence on treatment was increased in patients receiving
once-monthly ibandronate plus patient support compared
with once-weekly alendronate. Increased persistence on bis-
phosphonate treatment in patients with postmenopausal
osteoporosis is expected to improve patient outcomes and
decrease the social and economic burden of this debilitating
condition.
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